Glenn Reicin delivered his resignation as the Chief Financial Officer of Sigilon Therapeutics, Inc., effective June 14, 2021, to pursue a new professional opportunity with a privately held company. Effective June 14, 2021, Rogerio Vivaldi, M.D., the Company’s President and Chief Executive Officer, assumed the duties of the Company’s principal financial officer.